ARTICLE | Clinical News

Cell Therapeutics preclinical data

August 15, 1994 7:00 AM UTC

The Seattle company reported that CT-2576 blocked activation of the HIV-LTR promotor by tat or TNF-alpha, with minimal toxicity to the cells used for culture. The agent also prevented expression and cytokine-mediated expression of the p24 antigen in a cell line infected with the virus. ...